Psicose composition with excellent stability

Abstract

The present invention relates to a psicose composition having excellent stability.

Description

Technical Field

[0001] The present invention relates to a psicose composition having excellent stability. Background Art

[0002] Allulose is a diastereomer of D-fructose and is a functional carbohydrate called a rare sugar. It is known to have an effect on preventing and improving diabetes because it has almost zero calories while showing a high sweetness of about 60% to 70% of sugar. In addition, allulose is known to have excellent solubility and is one of the attractive substances used in food.

[0003] When the psicose syrup is stored for a long time, the psicose is converted into different substances or decomposed, resulting in a decrease in the psicose content. For example, psicose may be converted into different sugars (such as fructose, etc.) or furfural-based substances (such as HMF). Therefore, as the psicose syrup decomposes or converts into different substances during storage, the psicose content gradually decreases. Summary of the invention

[0004] Technical issues

[0005] One embodiment of the present invention relates to a psicose composition having excellent stability.

[0006] Another embodiment of the present invention is directed to a method for improving the stability of psicose by controlling the dissolved oxygen concentration in a psicose composition.

[0007] Technical Solution

[0008] One embodiment of the present invention relates to a psicose composition having excellent stability. Specifically, the psicose composition according to one embodiment of the present invention may have a dissolved oxygen (DO) concentration of 8 ppm or less to show excellent storage stability.

[0009] Another embodiment of the present invention relates to a method for improving the stability of psicose by controlling the dissolved oxygen content of a psicose composition. Specifically, the method for improving the stability of psicose according to one embodiment of the present invention can improve storage stability by reducing the dissolved oxygen (DO) concentration of the psicose composition. In the present invention, the storage stability of psicose means that the characteristics of psicose or psicose syrup measured immediately after preparation or at the beginning of storage are maintained, or the change of the characteristics during storage is minimized. The characteristics include psicose content, pH and / or color value, etc., but are not limited thereto.

[0010] Hereinafter, the present invention will be described in more detail.

[0011] An embodiment of the present invention relates to a psicose composition including dissolved oxygen below a specific concentration. The psicose composition may have a reduced rate of psicose content minimized during storage.

[0012] For example, the dissolved oxygen concentration of the psicose composition according to one embodiment of the present invention may be 10 ppm or less, 9.5 ppm or less, 9 ppm or less, 8.5 ppm or less, 8 ppm or less, 7.5 ppm or less, 7 ppm or less, 6.9 ppm or less, 6.8 ppm or less, 6.7 ppm or less, 6.6 ppm or less, 6.5 ppm or less, 6.4 ppm or less, 6.3 ppm or less, 6.2 ppm or less, 6.1 ppm or less, 6 ppm or less, 5.9 ppm or less, 5.8 ppm or less, 5.7 ppm or less, 5.6 ppm or less, 5.5 ppm or less, 5.4 ppm or less, 5.3 ppm or less, 5.2 ppm or less, 5.1 ppm or less, 5 ppm or less, 4.9 ppm or less, 4.8 ppm or less, 4.7 ppm or less, 4.6 ppm or less, 4.5 ppm or less, 4.4 ppm or less, 4.3 ppm or less, 4.2 ppm or less, 4.1 ppm or less, 4 ppm or less, 3.9 ppm or less, 3.8 ppm or less, 3.7 ppm or less, 3.6 ppm or less, 3.5 ppm or less, 3.4 ppm or less, 3.3 ppm or less, 3.2 ppm or less, 3.1 ppm or less, 3 ppm or less, 2.9 ppm or less, 2.8 ppm or less, 2.7 ppm or less, 2.6 ppm or less, 2.5 ppm or less, 2.4 ppm or less, 2.3 ppm or less, 2.2 ppm or less, 2.1 ppm or less, 2 ppm or less, 1.9 ppm or less, 1.8 ppm or less, 1.7 ppm or less, 1.6 ppm or less, or 1.5 ppm or less.

[0013] For example, the oxygen saturation rate of the psicose composition according to one embodiment of the present invention may be 90% saturation (sat) or less, 89% sat or less, 88% sat or less, 87% sat or less, 86% sat or less, 85% sat or less, 84% sat or less, 83% sat or less, 82% sat or less, 81% sat or less, 80% sat or less, 79% sat or less, 78% sat or less, 77% sat or less, 76% sat or less, or 77% sat or less. below, 75% sat below, 74% sat below, 73% sat below, 72% sat below, 71% sat below, 70% sat below, 69% sat below, 68% sat below, 67% sat below, 66% sat below, 65% sat below, 64% sat below, 63% sat below, 62% sat below, 61% sat below, 60% sat below, 59% sat below, 58% sat below, 57% sat below t or less, 56% sat or less, 55% sat or less, 54% sat or less, 53% sat or less, 52% sat or less, 51% sat or less, 50% sat or less, 49% sat or less, 48% sat or less, 47% sat or less, 46% sat or less, 45% sat or less, 44% sat or less, 43% sat or less, 42% sat or less, 41% sat or less, 40% sat or less, 39% sat or less, 38% sat or less The oxygen saturation rate is the oxygen saturation degree of the psicose composition, and is expressed based on the oxygen saturation degree in air of 100%. The oxygen saturation degree in air may be, for example, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25%.

[0014] The dissolved oxygen concentration or oxygen saturation rate can be measured under room temperature (20 to 30° C., for example, 24.5° C.).

[0015] An embodiment of the present invention may provide a psicose composition in which the psicose content measured immediately after preparation is maintained at a maximum value under storage conditions such as storage and distribution because the storage stability of the psicose composition is improved. In the present invention, the storage stability of the psicose composition may mean that the psicose content of the psicose composition is the same as that measured immediately after preparation, or that a decrease in the psicose content is minimized.

[0016] For example, based on 100 wt% of the solid content of psicose measured immediately after preparation of the psicose composition or at the start of storage, the rate of decrease in the solid content of psicose during storage is close to 0%, for example, the rate of decrease in the psicose content may be 10% or less, 9% or less, 8% or less, 7% or less, 6.5% or less, 6.3% or less, 6% or less, 5% or less, 4.5% or less, 4% or less, 3.5% or less, 3% or less, 2.5% or less, 2% or less, 1.9% or less, 1.8% or less, 1.7% or less, 1.6% or less, 1.5% or less, 1.4% or less, 1.3% or less, 1.2% or less, 1.1% or less, 1% or less, 0.9% or less, 0.8% or less, 0.7% or less, 0.6% or less, 0.5% or less, 0.4% or less, 0.3% or less, 0.2% or less, or 0.1% or less. For example, the reduction rate of the psicose content may refer to the reduction rate of the psicose content as described below, specifically, the psicose solid content (e.g., weight) contained in the psicose syrup measured immediately after preparation of the psicose syrup or at the beginning of storage, such as after storage at a temperature of 45° C. for 7 days or at a temperature of 35° C. for 4 weeks, based on 100% of the psicose content measured immediately after preparation of the psicose syrup or at the beginning of storage.

[0017] For example, the psicose composition according to one embodiment of the present invention may have a dissolved oxygen concentration of 8 ppm or less and a reduction rate of the psicose content of 5% or less after storage at a temperature of 45° C. for 7 days, a dissolved oxygen concentration of 6.7 ppm or less and a reduction rate of the psicose content of 1.4% or less after storage at a temperature of 45° C. for 7 days, a dissolved oxygen concentration of 6 ppm or less and a reduction rate of the psicose content of 1.1% or less after storage at a temperature of 45° C. for 7 days, or a dissolved oxygen concentration of 4.3 ppm or less and a reduction rate of the psicose content of 1.0% or less after storage at a temperature of 45° C. for 7 days.

[0018] For example, the psicose composition according to one embodiment of the present invention may have a dissolved oxygen concentration of 8 ppm or less and a reduction rate of the psicose content of 10% or less after storage at a temperature of 35° C. for 4 weeks, a dissolved oxygen concentration of 6.7 ppm or less and a reduction rate of the psicose content of 6.5% or less after storage at a temperature of 35° C. for 4 weeks, a dissolved oxygen concentration of 5 ppm or less and a reduction rate of the psicose content of 6.3% or less after storage at a temperature of 35° C. for 4 weeks, or a dissolved oxygen concentration of 3.9 ppm or less and a reduction rate of the psicose content of 6% or less after storage at a temperature of 35° C. for 4 weeks.

[0019] The psicose composition according to one embodiment of the present invention has improved storage stability, and thus the pH of the psicose composition under storage conditions such as storage and distribution may be the same as the pH measured immediately after preparation, or a pH decrease may be minimized.

[0020] Therefore, a decrease in pH can be prevented in the psicose composition according to one embodiment of the present invention. For example, the difference in the decreased pH of the psicose composition after storage at a temperature of 35° C. for 4 weeks may be 1 or less, 0.9 or less, 0.85 or less, 0.8 or less, 0.75 or less, 0.7 or less, 0.65 or less, 0.6 or less, or 0.55 or less, based on the pH immediately after preparation of the psicose composition or at the beginning of storage. For example, the psicose composition according to one embodiment of the present invention may have a difference in dissolved oxygen concentration of 8 ppm or less and a decreased pH of 1 or less after storage at a temperature of 35° C. for 4 weeks, a difference in dissolved oxygen concentration of 6.7 ppm or less and a decreased pH of 0.83 or less after storage at a temperature of 35° C. for 4 weeks, a difference in dissolved oxygen concentration of 5 ppm or less and a decreased pH of 0.7 or less after storage at a temperature of 35° C. for 4 weeks, or a difference in dissolved oxygen concentration of 3.9 ppm or less and a decreased pH of 0.65 or less after storage at a temperature of 35° C. for 4 weeks.

[0021] Since the decomposition of psicose is accelerated at low pH, pH is a very important factor for the stability of psicose content. Since the psicose syrup according to an embodiment of the present invention has a very small difference in reduced pH during storage, the psicose content can be maintained at a maximum value.

[0022] The psicose composition according to one embodiment of the present invention has improved storage stability, and thus the color value of the psicose composition under storage conditions such as storage and distribution may be the same as the color value measured immediately after preparation, or an increase in color value (e.g., browning) may be minimized.

[0023] Therefore, in the psicose composition according to one embodiment of the present invention, browning can be prevented. For example, based on the color value measured immediately after the preparation of the psicose composition or at the beginning of storage, the increase rate of the color value after storage at a temperature of 35° C. for 4 weeks may be 250% or less, 240% or less, 230% or less, 225% or less, 220% or less, 210% or less, 205% or less, 200% or less, 190% or less, 185% or less, 180% or less, 175% or less, 170% or less, 165% or less, 160% or less, 155% or less, 150% or less, 145% or less, 140% or less, 135% or less, 130% or less, 125% or less, 120% or less, 115% or less, or 110% or less.

[0024] The psicose composition according to one embodiment of the present invention may be in the form of a liquid or a syrup. The solid content of the liquid psicose composition or the psicose syrup may be, for example, 30 Brix or more, 40 Brix or more, 50 Brix or more, 60 Brix or more, higher than 60 Brix, or 64 Brix or more. For example, the solid content of the psicose liquid composition or the psicose syrup may be 30 to 99 Brix, 30 to 95 Brix, 30 to 90 Brix, 30 to 85 Brix, 30 to 80 Brix, 30 to 75 Brix, 30 Brix or more and less than 73 Brix, 30 to 70 Brix, 30 to 69 Brix, 30 to 68 Brix, 40 to 99 Brix, 40 to 95 Brix, 40 to 90 Brix, 40 to 85 Brix, 40 to 45 Brix, 40 to 50 Brix, 40 to 65 Brix, 40 to 75 Brix, 30 to 85 Brix, 40 to 80 Brix, 40 to 85 Brix, 40 to 99 Brix, 40 to 95 Brix, 40 to 9 ...95 Brix, 40 to 90 Brix, 40 to 85 Brix, 40 to 95 to 80 Brix, 40 to 73 Brix or more, 40 to 75 Brix, 40 to 70 Brix, 40 to 69 Brix, 40 to 68 Brix, 50 to 99 Brix, 50 to 95 Brix, 50 to 90 Brix, 50 to 85 Brix, 50 to 80 Brix, 50 to 75 Brix, 50 to 73 Brix or more, 50 to 70 Brix, 50 to 69 Brix, 50 to 68 Brix, 60 to 9 9 Brix, 60 to 95 Brix, 60 to 90 Brix, 60 to 85 Brix, 60 to 80 Brix, 60 to 75 Brix, 60 Brix and below 73 Brix, 60 to 70 Brix, 60 to 69 Brix, 60 to 68 Brix, above 60 and below 99 Brix, above 60 and below 95 Brix, above 60 and below 90 Brix, above 60 and below 85 Brix, above 60 and below 80 Brix, above 60 and below 75 Brix, above 60 and below 73 Brix, above 60 and below 70 Brix, above 60 and below 69 Brix, above 60 and below 68 Brix, 64 to 99 Brix, 64 to 95 Brix, 64 to 90 Brix, 64 to 85 Brix, 64 to 80 Brix, 64 to 75 Brix, above 64 Brix and below 73 Brix, 64 to 70 Brix, 64 to 69 Brix or 64 to 68 Brix.

[0025] The psicose liquid composition or psicose syrup may include 0.1 wt % or more, 3 wt % or more, 5 wt % or more, 10 wt % or more, 20 wt % or more, 30 wt % or more, 40 wt % or more, 50 wt % or more, 60 wt % or more, or for example, 0.1 to 100 wt % of psicose based on 100 wt % of solid content. For example, it may be a low-purity psicose syrup including 1 to 50 wt %, 3 to 35 wt %, 3 to 25 wt %, 3 to 20 wt %, 5 to 35 wt %, 5 to 25 wt %, or 5 to 20 wt %, or a high-purity psicose solution including 70 wt %, 75 wt %, 80 wt %, 85 wt %, 90 wt %, 95 wt %, 96 wt %, 97 wt % or more, or 98 wt % or more of solid content based on 100 wt %.

[0026] The viscosity of the allulose syrup may be 2 cps to 200 cps at a temperature of 45° C., and the conductivity thereof may be 1000 uS / cm or less, for example, 0.01 to 1000 uS / cm, 200 uS / cm or less, 150 uS / cm or less, 100 uS / cm or less, 80 uS / cm or less, 50 uS / cm or less, 30 uS / cm or less, for example, 0.1 to 200 uS / cm, 0.1 to 150 uS / cm, 0.1 to 100 uS / cm, 0.1 to 0.1 to 80 uS / cm, 0.1 to 50 uS / cm, or 0.1 to 30 uS / cm.

[0027] In the psicose syrup according to one embodiment of the present invention, the pH at the beginning of storage may be 2.8 or more or 5.5 or less. For example, it may be 2.8 to 5.5, 3.8 to 5.5, 3.9 to 5.5, 4.0 to 5.5, 4.1 to 5.5, 4.2 to 5.5, 4.3 to 5.5, 4.4 to 5.5, 4.5 to 5.5, 4.6 to 5.5, 4.7 to 5.5, or 4.8 to 5.5.

[0028] In a specific embodiment, the psicose syrup can be obtained by subjecting a biologically obtained psicose-containing solution to a preparation method including activated carbon treatment, SMB chromatography high-purity separation, and an ion purification process, and optionally, a process of concentrating the psicose syrup treated by the purification process can be further performed, or an ion purification process can be further performed after the activated carbon treatment process of the psicose-containing solution and before the high-purity separation. The ion purification process performed after the activated carbon treatment process may be the same as or different from the ion purification process performed after the high-purity separation process, and the ion exchange resin is not particularly limited.

[0029] The psicose-containing solution obtained by the organism can be produced by culturing a microorganism producing psicose epimerase or a recombinant microorganism into which a gene encoding psicose epimerase is introduced, and reacting the microorganism producing psicose epimerase or the psicose epimerase obtained therefrom with a fructose-containing raw material. The psicose epimerase can be carried out by a liquid reaction or a solid reaction using an immobilized enzyme. An example of a psicose conversion reaction is described in Korean Patent No. 10-1318422, etc.

[0030] The psicose-containing solution is separated into a psicose fraction having a higher psicose content than the conversion reactant and the fructose residual liquid by performing SMB chromatography separation, and the psicose fraction can be prepared into a psicose syrup product by performing an ion purification process, or can be prepared into a concentrated product by performing a concentration process separately. This may include separation / purification such that the psicose content in the psicose fraction is 85 wt % or more, for example, 85 wt % to 95 wt % (w / w) or more.

[0031] Another embodiment of the present invention relates to a psicose storage kit, comprising a psicose composition according to one embodiment of the present invention and a storage container. Since the kit is sealed, the dissolved oxygen concentration of the psicose composition may not change or the change in the dissolved oxygen concentration may be minimized.

[0032] The storage container for psicose suitable for the present invention includes a container body, a storage space is formed therein and an inlet connected to the storage space is formed therein, and a cover member is detachably connected to the inlet of the container body and seals the storage space. The appearance or shape of the container is not particularly limited.

[0033] The storage container can be made of metal, metal alloy or polymer material. When using metal or metal alloy material, the inner surface of the container is coated with polymer so that direct contact with D-psicose syrup can be preferably minimized. The coating of the inner surface of the container preferably coats the entire surface in the container, and the coating includes a single coating, a secondary coating or multiple coatings with more than three coatings. It can be multiple coatings more than twice to minimize direct contact of D-psicose syrup with metal or metal alloy material. The metal or metal alloy material is not particularly limited, as long as it is a material that can be used for food containers, for example, the container can be tin or tin alloy material. The coating agent on the inner surface of the container is not particularly limited, as long as it is a material that can be used for food containers, for example, it can be an epoxy phenolic resin that can be used for food containers, and the inner surface of the container can include a coating of the epoxy phenolic resin, specifically, it can be a commercially available product, Canguard 5K-872 (product name).

[0034] Another embodiment of the present invention is directed to a method for improving the stability of psicose, comprising adjusting dissolved oxygen of a psicose composition.

[0035] A further embodiment of the present invention relates to a method for preventing browning of psicose, comprising adjusting dissolved oxygen (DO) of a psicose composition.

[0036] Other embodiments of the present invention relate to a method for preparing a psicose composition, comprising obtaining a crude psicose composition by converting fructose into psicose, and adjusting dissolved oxygen of the crude psicose composition.

[0037] Adjusting the dissolved oxygen may be reducing the dissolved oxygen. Reducing the dissolved oxygen may be removing the dissolved oxygen in the psicose composition, or preventing an increase in the dissolved oxygen in the psicose composition.

[0038] Adjusting the dissolved oxygen may include at least one selected from the following (1) to (5):

[0039] (1) treating the psicose composition with a deoxidizing agent;

[0040] (2) packaging the psicose composition with a selectively permeable packaging material;

[0041] (3) Perform inert gas replacement;

[0042] (4) vacuum degassing; and

[0043] (5) adjusting (e.g., reducing) the head space of a container in which the psicose composition is contained.

[0044] The selectively permeable packaging material may be an oxygen-impermeable packaging material.

[0045] The inert gas replacement is to replace dissolved oxygen in the psicose composition with an inert gas. The inert gas means a gas that does not reduce the psicose content, or a gas that has a lower degree of reducing the psicose content than oxygen.

[0046] Adjusting the dissolved oxygen may be controlling the dissolved oxygen concentration of the psicose composition to be below 8 ppm or the oxygen saturation to be below 90% sat.

[0047] Beneficial Effects

[0048] The psicose composition according to one embodiment of the present invention has a high psicose content maintenance rate and excellent storage stability because it contains a specific range of dissolved oxygen concentration. Therefore, even if the psicose syrup is stored and distributed for a long time, decomposition or conversion of psicose is prevented, thereby minimizing the reduction of the psicose content. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 : is a graph showing the rate of change in the psicose content after storing the psicose composition according to one embodiment of the present invention at a temperature of 35° C. for 4 weeks. DETAILED DESCRIPTION

[0050] Hereinafter, the present invention will be described in more detail by the following examples. However, these examples are only intended to illustrate the present invention, and the scope of the present invention is not limited by these examples.

[0051] Example 1: Stability of D-psicose Syrup According to Dissolved Oxygen Concentration (1)

[0052] In order to study the effect of dissolved oxygen concentration of psicose syrup on the stability of psicose content, psicose syrup samples with different dissolved oxygen concentrations were stored under harsh conditions for 7 days, and then the changes in psicose content were measured.

[0053] Specifically, a sample container made of polyethylene with a capacity of 500 ml was added with a psicose syrup (liquid sample) having a psicose purity of 98% by weight, pH 4.1, and a solid content of 60 degrees Brix, and the psicose syrup was stirred to adjust the dissolved oxygen concentration. The stirring rate was changed from 150 to 200 rpm, and the stirring time was changed from 0 to 30 seconds, so that the dissolved oxygen concentration was measured in real time with a DO meter (Hanna edge Do meter). A saturated dissolved oxygen concentration of 10 to 20% can be adjusted by only ventilation without stirring, while a higher value is adjusted by changing the stirring rate and stirring time, and when the saturated dissolved oxygen concentration reaches a certain value, it is immediately sealed so that the dissolved oxygen concentration can be maintained. The four dissolved oxygen concentrations of the prepared psicose syrups are shown in Table 1.

[0054] The accelerated test was performed by storing each Psicose syrup sample at a temperature of 45°C, collecting a small amount of each sample after 7 days of storage, and diluting to 3 degrees Brix by adding water to prepare an analytical sample. The Psicose content of the analytical sample was measured by HPLC analysis. The specific HPLC analysis conditions were to use an 87C (Biorad HPX-87C, 7.8mm Φ x300mm) column at a temperature of 80°C by flowing 100% water as a mobile phase at a flow rate of 0.6 ml / min, and to detect using an RI detector. In Table 1, the Psicose content is expressed as the Psicose content based on 100% by weight of the solid content of the Psicose syrup.

[0055] [Table 1]

[0056]

[0057] Example 2: Stability of D-psicose Syrup According to Dissolved Oxygen Concentration (2)

[0058] Using psicose syrup having a psicose purity of 98 w / w%, pH 4.1, and a solid content of 64 degrees Brix, testing was performed according to substantially the same method as Example 1, and the differences in the psicose content and the rate of change of the psicose content according to dissolved oxygen concentration are shown in Table 2.

[0059] [Table 2]

[0060]

[0061] Example 3: Stability of D-psicose Syrup According to Dissolved Oxygen Concentration (3)

[0062] Using psicose syrup having a psicose purity of 98 w / w%, pH 4.1, and a solid content of 68 degrees Brix, testing was performed according to substantially the same method as Example 1, and the differences in the psicose content and the rate of change of the psicose content according to the dissolved oxygen concentration are shown in Table 3.

[0063] [Table 3]

[0064]

[0065] Example 4: Stability of D-psicose Syrup According to Dissolved Oxygen Concentration (4)

[0066] Using psicose syrup having a psicose purity of 98 w / w%, pH 4.1, and a solid content of 73 degrees Brix, testing was performed according to substantially the same method as Example 1, and the differences in the psicose content and the rate of change of the psicose content according to dissolved oxygen concentration are shown in Table 4.

[0067] [Table 4]

[0068]

[0069] As shown in Tables 1 to 4, the psicose loss rate decreased as the dissolved oxygen concentration of the psicose syrup decreased. Specifically, when stored at a temperature of 45° C. for 7 days, the psicose content reduction rate of the psicose syrup having a dissolved oxygen concentration of 8 ppm or less or an oxygen saturation rate of 90% sat or less was 5% or less, and the storage stability of the psicose syrup was remarkably excellent.

[0070] Example 5: Stability of D-psicose Syrup Depending on Dissolved Oxygen Concentration During Long-term Storage (1)

[0071] In order to investigate the effect of dissolved oxygen concentration on the stability of the psicose content when the psicose syrup was stored for a long time, psicose syrup samples having different dissolved oxygen concentrations were stored for 4 weeks, and then changes in the psicose content were measured.

[0072] Specifically, a psicose syrup having a psicose purity of 97% or more, a pH of 4.15, and a solid content of 60 degrees Brix was prepared, and the dissolved oxygen concentration was adjusted by the same method as in Example 1. Then, after storing each sample at 35° C. for 4 weeks, the psicose content was measured and the psicose content change rate was calculated and reported in Tables 5 and 6. Figure 1 In Table 5, the psicose content is expressed as the psicose content based on 100 wt % of the solid content of the psicose syrup.

[0073] [Table 5]

[0074]

[0075] Example 6: Stability of D-psicose Syrup Depending on Dissolved Oxygen Concentration During Long-term Storage (2)

[0076] Using psicose syrup having a psicose purity of more than 97%, a pH of 4.15, and a solid content of 64 degrees Brix, the test was conducted according to substantially the same method as in Example 5. The change amount and change rate of the psicose content according to the dissolved oxygen concentration are shown in Tables 6 and 7. Figure 1 In Table 6, the psicose content is expressed as the psicose content based on 100 wt % of the solid content of the psicose syrup.

[0077] [Table 6]

[0078]

[0079] Example 7: Stability of D-psicose Syrup Depending on Dissolved Oxygen Concentration During Long-term Storage (3)

[0080] Using psicose syrup having a psicose purity of more than 97%, a pH of 4.15, and a solid content of 68 degrees Brix, the test was conducted according to substantially the same method as in Example 5. The change amount and change rate of the psicose content according to the dissolved oxygen concentration are shown in Tables 7 and 8. Figure 1 In Table 7, the psicose content is expressed as the psicose content based on 100 wt % of the solid content of the psicose syrup.

[0081] [Table 7]

[0082]

[0083] Example 8: Stability of D-psicose Syrup Depending on Dissolved Oxygen Concentration During Long-term Storage (4)

[0084] Using psicose syrup having a psicose purity of more than 97%, a pH of 4.15, and a solid content of 73 degrees Brix, the test was conducted according to substantially the same method as in Example 5. The change amount and change rate of the psicose content according to the dissolved oxygen concentration are shown in Tables 8 and 9. Figure 1 In Table 8, the psicose content is expressed as the psicose content based on 100 wt % of the solid content of the psicose syrup.

[0085] [Table 8]

[0086]

[0087] As shown in Tables 5 to 8, the lower the dissolved oxygen concentration of the psicose syrup, the lower the psicose loss rate. Specifically, when stored at a temperature of 35° C. for 4 weeks, the psicose content reduction rate of the psicose syrup having a dissolved oxygen concentration of 8 ppm or less or an oxygen saturation rate of 90% sat or less was 10% or less, and the storage stability of the psicose syrup was remarkably excellent. In particular, as shown in Figure 1 , it is shown that the change of the psicose content caused by the dissolved oxygen concentration in the psicose syrup having a value of 64 degrees Brix or more is significant.

[0088] Therefore, quality deterioration in which the psicose content decreases during the shelf life can be prevented by adjusting the dissolved oxygen concentration in the psicose syrup, and a psicose syrup having an excellent effect of maintaining the psicose content and high stability can be provided.

[0089] Example 9: pH stability of psicose syrup according to dissolved oxygen concentration

[0090] The pH of the samples of the psicose syrups used in Examples 5 to 8 was measured immediately after preparation and after storage at a temperature of 35° C. for 4 weeks. The difference in pH values ​​was calculated and shown in Table 9.

[0091] [Table 9]

[0092]

[0093] As shown in Table 9, the lower the dissolved oxygen concentration, the lower the pH decrease. Specifically, when stored at a temperature of 35° C. for 4 weeks, the difference in pH decrease of the psicose syrup having a dissolved oxygen concentration of 8 ppm or less or an oxygen saturation rate of 90% sat or less was 1 or less, and the pH stability of the psicose syrup was significantly excellent.

[0094] Example 10: Color stability of psicose syrup according to dissolved oxygen concentration

[0095] The color values ​​of the samples of the psicose syrups used in Examples 5 to 8 were measured immediately after preparation and after storage at 35° C. for 4 weeks. The color value change rate was calculated and shown in Table 10. The color value was measured using a spectrophotometer (SHIMADZU) at 420 nm using a 1 cm quartz cell after diluting the psicose syrup to 30 degrees Brix.

[0096] [Table 10]

[0097]

[0098] As shown in Table 10, the color value change rate decreased as the dissolved oxygen concentration decreased. This means that the browning of psicose syrup can be prevented by adjusting the dissolved oxygen concentration of psicose syrup.

Claims

1. A liquid psicose composition comprising psicose and having a dissolved oxygen (DO) concentration of 8 ppm or less or an oxygen saturation rate of 90% saturation (sat) or less.

2. The composition of claim 1, wherein the composition has a solids content of 30 to 99 degrees Brix. 3 . The composition according to claim 1 , wherein the psicose content of the composition is 5 wt % or more based on 100 wt % of the total solid content of the composition.

4. The composition according to claim 1, wherein the pH of the composition is 2.8 to 5.

5. The composition according to claim 1 , wherein the composition has a psicose content reduction rate of 10% or less based on the psicose content at the beginning of storage after storage at a temperature of 45° C. for 7 days. The composition according to claim 1 , wherein the composition has a Psicose content reduction rate of 10% or less based on the Psicose content at the beginning of storage after storage at a temperature of 35° C. for 4 weeks. 7 . The composition according to claim 1 , wherein the composition has a pH decrease value of 1 or less based on the pH at the beginning of storage after storage at a temperature of 35° C. for 4 weeks. 8 . The composition according to claim 1 , wherein the composition has a color value increase rate of 250% or less based on the color value at the beginning of storage after being stored at a temperature of 35° C. for 4 weeks. 9 . A psicose storage kit, comprising the composition according to any one of claims 1 to 8 and a storage container.

10. The kit of claim 9, wherein the kit is sealed.

11. A method for improving the stability of psicose, comprising reducing dissolved oxygen (DO) of a psicose composition.

12. The method according to claim 11, wherein reducing dissolved oxygen comprises at least one selected from the group consisting of (1) to (5): (1) Treat with deoxidizer; (2) packaging with selectively permeable packaging materials; (3) Perform inert gas replacement; (4) vacuum degassing; and (5) Adjusting the head space of a container in which the psicose composition is contained. 13 . The method according to claim 11 , wherein reducing dissolved oxygen is adjusting the dissolved oxygen concentration of the psicose composition to below 8 ppm, or adjusting the oxygen saturation rate of the psicose composition to below 90% sat.

14. A method for preventing browning of psicose, comprising reducing dissolved oxygen (DO) of a psicose composition.

15. A method for preparing a psicose composition, comprising obtaining a psicose composition by converting fructose into psicose; and The dissolved oxygen (DO) of the psicose composition is reduced.

16. The method according to claim 15, wherein reducing dissolved oxygen comprises at least one selected from the group consisting of (1) to (5): (1) Treat with deoxidizer; (2) packaging with selectively permeable packaging materials; (3) Perform inert gas replacement; (4) vacuum degassing; and (5) Adjusting the head space of a container in which the psicose composition is contained. 17 . The method according to claim 15 , wherein reducing dissolved oxygen is adjusting the dissolved oxygen concentration of the psicose composition to below 8 ppm, or adjusting the oxygen saturation rate of the psicose composition to below 90% sat.

Images